Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Abacavir sulfate Clear all

Conditions: HIV-1-infection
Interventions: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 38
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 16 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Plaque Psoriasis
Interventions: Prurisol, Placebo; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 37
States / cities: Fountain Valley, California • Los Angeles, California • Sacramento, California + 31 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 23
States / cities: Concord, California • Long Beach, California • Orlando, Florida + 15 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more

Conditions: Chronic Stroke
Interventions: Virtual reality based dance group, Active Comparator: Control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Abacavir/Lamivudine, Lersivirine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC, Ongoing cART regimen; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 87
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 62
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 43 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 55
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 32 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: Trizivir, atazanavir, Combivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 43
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 35 more

Conditions: HIV-1-infection
Interventions: Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine, Switch; Other · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Efavirenz; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: HIV Infections
Interventions: Tenofovir, Abacavir; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 5
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 2 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 3 Months to 12 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Amprenavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Reyataz + Norvir + Truvada, Reyataz + Epzicom; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 44
States / cities: Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Abacavir sulfate, lamivudine, and zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 19
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 15 more

Conditions: HIV Infections
Interventions: Maraviroc; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of Novel Antiretrovirals in Participants With HIV-1

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

Active Balance and Cardio Care Intervention on Physical and Cardiovascular Health in People With Chronic Stroke

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Blood Levels of Abacavir in HIV Infected Adolescents

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc